Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

K Patterson; V Prabhu; RF Xu; HJ Li; Y Meng; N Zarabi; YC Zhong; R Batteson; J Pellissier; S Keefe; P Grivas; Ronald de Wit

doi:10.1016/j.euo.2018.09.009

Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

K Patterson, V Prabhu, RF Xu, HJ Li, Y Meng, N Zarabi, YC Zhong, R Batteson, J Pellissier, S Keefe, P Grivas, Ronald de Wit

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Scopus)

30 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	565-571
Number of pages	7
Journal	European urology oncology
Volume	2
Issue number	5
DOIs	https://doi.org/10.1016/j.euo.2018.09.009
Publication status	Published - 2019

Research programs

EMC MM-03-86-08

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euo.2018.09.009

Repub_121262_O-A.pdfFinal published version, 989 KB

http://hdl.handle.net/1765/121262

Cite this

Patterson, K., Prabhu, V., Xu, RF., Li, HJ., Meng, Y., Zarabi, N., Zhong, YC., Batteson, R., Pellissier, J., Keefe, S., Grivas, P., & de Wit, R. (2019). Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. European urology oncology, 2(5), 565-571. https://doi.org/10.1016/j.euo.2018.09.009

@article{71067981061445c591068c49b6b3e704,

title = "Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy",

author = "K Patterson and V Prabhu and RF Xu and HJ Li and Y Meng and N Zarabi and YC Zhong and R Batteson and J Pellissier and S Keefe and P Grivas and {de Wit}, Ronald",

year = "2019",

doi = "10.1016/j.euo.2018.09.009",

language = "Undefined/Unknown",

volume = "2",

pages = "565--571",

journal = "European urology oncology",

issn = "2588-9311",

publisher = "Elsevier",

number = "5",

}

Patterson, K, Prabhu, V, Xu, RF, Li, HJ, Meng, Y, Zarabi, N, Zhong, YC, Batteson, R, Pellissier, J, Keefe, S, Grivas, P & de Wit, R 2019, 'Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy', European urology oncology, vol. 2, no. 5, pp. 565-571. https://doi.org/10.1016/j.euo.2018.09.009

TY - JOUR

T1 - Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

AU - Patterson, K

AU - Prabhu, V

AU - Xu, RF

AU - Li, HJ

AU - Meng, Y

AU - Zarabi, N

AU - Zhong, YC

AU - Batteson, R

AU - Pellissier, J

AU - Keefe, S

AU - Grivas, P

AU - de Wit, Ronald

PY - 2019

Y1 - 2019

U2 - 10.1016/j.euo.2018.09.009

DO - 10.1016/j.euo.2018.09.009

M3 - Article

C2 - 31412011

SN - 2588-9311

VL - 2

SP - 565

EP - 571

JO - European urology oncology

JF - European urology oncology

IS - 5

ER -